Treatment options of polycystic ovary syndrome in adolescence

Pediatric Endocrinology Reviews

Volumn 3, Issue SUPPL. 1, 2006, Pages 208-213

  Evangelia, Zapanti ^a,c   Erasmia, Kiapekou ^a   Dimitrios, Loutradis ^b  

^a ALEXANDRA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NONE   (Greece)

Author keywords

Adolescence; Hirsutism; Hyperandrogenism; Insulin resistance; Menstrual irregularities; Obesity; PCOs; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALDOSTERONE ANTAGONIST; ANDROGEN; ANTIANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SPIRONOLACTONE; TROGLITAZONE;

ADOLESCENT; ADOLESCENT DISEASE; AMENORRHEA; ANEMIA; ANOVULATION; APPETITE DISORDER; BLEEDING DISORDER; BODY WEIGHT DISORDER; BREAST TENDERNESS; CONFERENCE PAPER; DISEASE ASSOCIATION; DIURESIS; EDEMA; FATIGUE; FEMALE; FLUID RETENTION; HEADACHE; HUMAN; HYPERANDROGENISM; HYPERKALEMIA; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIBIDO DISORDER; LIVER DYSFUNCTION; LIVER FAILURE; MENSTRUAL IRREGULARITY; MOOD DISORDER; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PREMENOPAUSE; RISK ASSESSMENT; STEROIDOGENESIS; TERATOGENICITY; TREATMENT OUTCOME; UTERUS BLEEDING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; WEIGHT LOSS;

EID: 33645402365     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Franks S. Adults polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002;16:263-272
2. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:341-359
3. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjiansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257-1266
4. Yen SS. The polycystic ovary syndrome. Clin Endocrinol 1980; 12:177-207
5. Legro RS, Kunseiman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169
6. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346:802-810
7. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovary syndrome. J Clin Endorinol Metab 1983;57:356-359
8. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjiansky A. Characterization of groups of hyperandrogenemic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endorinol Metab 1987;65:499-507
9. Dunaif A, Segal KR, Futterweit W, Dobrjiansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome 1989;38:1165-1174
10. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanisms and implications for pathogenesis. Endocr Rev 1997; 18:774-800
11. Nestler JE, Jakubwicz DJ, De Vargas AF, Brik C, Quintero N, and Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endorinol Metab 1998;83:2001-2005
12. Willis D, Franks S. Insulin action in human granulose cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-1 insulin-like growth factor receptor. J Clin Endorinol Metab 1995;80:3788-3790
13. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999;28:361-378
14. Nelson VL, Qin Kn KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, Strauss JF 3rd, McAllister JM. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925-5933
15. Ibanez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 1996;81:4103-4107
16. Gilling-Smith C, Story H, Rogers V and Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinology 1997;47:93-99
17. Sam S, Dunaif A. Polycystic ovary syndrome: Syndrome XX? Trends in Endocrinology and Metabolism 2003;14:365-370
18. Urbanek M. Thirty - seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with Follistatin. Proc. Natl. Acad. Sci. USA 1999:96,8573-8578
19. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Endocrine features of polycystic ovary syndrome in a random population of 14-16 year oil adolescents. Hum Reprod 1999;14:2223-2229
20. Oppenheimer E, Linder B, Dimartino-Nardi J. Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans. J Clin Endocrinol Metab 1995;80:614-618
21. Ibanez L, Potau N, Zampolli M, Prat N, Virdis R, Vicens-calvet E, Carrascosa A. Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1996;81:1237-1243
22. Rosenfield RL, Ghai K, Ehrmann DA and Barnes RB. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab 13 Suppl 2000;5:1285-1289
23. Plouffe Jr L. Disorders of excessive hair growth in the adolescent. Obstet Gynecol Clin North Am 2000;27:779-799
24. Homburg R, Lambalk CB. Debate: Polycystic ovary syndrome in adolescence-a therapeutic conundrum. Hum Reprod 2004;19:1039-1042
25. Samantha M. Pfeifer, MD Polycystic ovary syndrome in adolescent girls. Seminars in Pediatric Surgery 2005;14:111-117
26. Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin N Am 2003;30:337-352
27. Legro RS, Kunslman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab 1999;84:165-169
28. Kent SC and Legro RS. Polycystic ovary syndrome in adolescents. Adolesc Med 2002;13:73-88
29. Pasquali R, Antenucci D, Casmirri F, Venturoli S, Paradisi R, Fabbri R, Balestra V, Melchionda N and Barbara L. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68:173-179
30. Azziz R, Gay F. The treatment of hyperandrogenism with oral contraceptives. Semin Reprod Endocrinol 1989;7:246-254
31. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertility and Sterility 2002:77(5)919-927
32. Rittmaster RS. Medical treatment of androgen-dependent hirsutism: clinical review. J Clin Endocrinol Metab 1995;80:2559-2563
33. Pittaway DE. Evaluation and treatment of unresponsive hirsutism. Sex Med Today 1985;3:14-18.
34. Rittmaster RS. Medical treatment of androgen-dependent hirsutism: clinical review. J Clin Endocrinol Metab 1995;80:2559-2563
35. Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA 1982;247:1295-1298
36. Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985;43:200-205
37. Moghetti P, Tosi F, Castello, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952-960
38. Helfer EL, Miller JL and Rose LI. Side-effects of spironolactone therapy in the hirsute woman. J Clin Endocrinol Metab 1988;66:208-211
39. Schultz M, Schmoldt A, Donn F and Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Pharmacol 1988;34:633-635
40. Del Leo V, Lanzetta D, D'Antona A, Samarca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99-102
41. Ibanez L, Potau N, Marcos MV, de Degher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effects of flutamide. J Clin Endocrinol Metab 2000;85:3251-3255
42. Wysowski DK, Fourcroy JL. Safety of flutamide? Fertil Steril., 1994;62:1089-1990.
43. Reaven GM. Banting lecture, 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
44. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care, 1991;14:195-202.
45. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146
46. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325-340
47. Lord JM, Flight IM, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. BMJ 2003;327:951-953
48. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hiero F and de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-3598
49. Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, and de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004;144:23-29
50. Coetzee EJ, Jackson WPU. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979;16:241-245
51. Yoshioka T, Aizawa Y, Fujita T, Nakamura K, Sasahara K, Kuwano H, Kinoshita T, Horikoshi H. Studies on hindered phenols and analogues. V. Synthesis, identification and antidiabetic activity of the glucuronide of CS-045. Chem. Pharm. Bull 1991;39:2124-2125
52. Henry R. Thiazolidinedions: in current therapies for diabetes. Endocrinol. Metab. Clin. N Am 1997;26:553-573
53. Bahr M, Spelleken M, Bock M von Holtey M, Kiehn R, Eckel J. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia 1996;39:766-774
54. Ehrmann DA, Schneider DJ, Sobel BE, Cavagham MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with PCOS. J Clin Endocrinol Metab 1997;82:2108-2011
55. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, and Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003;79:932-937
56. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol. Metab 1995;80:3327-3334
57. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod 1998;13:2706-2711
58. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertility and Sterility, 2006 (In Press)
59. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Hennekens CH, Speizer FE. Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 1992;35:967-972
60. Chasan-Taber L., Willett WC, Stampfer MJ, Hunter DJ, Golditz GA, Spiegelman D, Manson JE. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 1997;20:330-335
61. Ganie MA, Khurana ML, Eunice M, Gulati M, Dwivedi SN, Amniti AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labelled study. J Clin. Endocrinol Metab 2004;89(6):2756-2762
62. Ibanez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low dose flutamide - metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J. Clin. Endocrinol. Metab., 2003;88:2600-2606.
63. Ibanez L, de Zegher F. Ethinylestradiol-Drospirone, Flutamide-Metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89:1592-1597
64. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol 1996;8:253-278
65. Weiss R, Dufour S, Groszmann A, Petersen K, Dziura J, Taksali SE, Shulman G, Caprio S. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab 2003;88:2014-2018
66. Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, Pugeat AI. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol. Metab 2003;88:3626-3631
67. Glueck C, Moreira A, Goldenberg N, Sieve L and Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003;18:1618-1625